Il tuo browser è obsoleto

Con un browser aggiornato, l'esperienza di navigazione sul sito Web di Medtronic sarà migliore. Aggiorna il mio browser adesso.

CLINICAL EVIDENCE — PROVEN PLATFORM TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)

The Evolut TAVI System Proven Platform

The Evolut^TM TAVI System is built on a proven platform that provides industry-leading hemodynamics, advanced sealing and a low-profile delivery. The CoreValve^TM TAVI platform is the only TAVI platform currently on the market that demonstrates significantly better outcomes in all-cause mortality or stroke over surgery in high-risk patient at 3 years.¹

COREVALVE U.S. PIVOTAL HIGH RISK TRIAL²

The CoreValve U.S. Pivotal High Risk Trial is a prospective, randomized, multicenter, noninferiority trial to compare the safety and efficacy of the Medtronic CoreValve system to SAVR in patients with symptomatic severe aortic stenosis at increased surgical risk.

Study Status/Duration: 3-year outcomes reported/5-year follow-up
Sample Size: N = 795 (TAVR = 391, SAVR = 359)
Devices: CoreValve TAV

Download STudy (opens new window)

(opens new window)
View Larger(opens new window)

The Medtronic TAVI supra-annular valve design contributes to industry-leading hemodynamics.

SEE INDUSTRY-LEADING HEMODYNAMIC DATA

CONTATTI

Medtronic Italia

+39 02 241371
Via Varesina 162
20156 Milano Italia

CONTACT US

For any information

CLICK HERE

MEDTRONIC ACADEMY

View more clinical data and access procedural resources.

Deeb, et al. (2015) presentation

Deeb GM, Reardon MJ, Chetcuti S, et al. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. June 7, 2016;67(22):2565-2574.